• Company Information
  • Business Outline
  • Pipeline
  • IR Information
  • Contact
Breakthrough virotherapy for cancer

Oncolys BioPharma continuously evolve its business to develop breakthrough therapy and diagnostics in cancer treatment from early to late stage, including early detection, loco-regional therapy, prognostic test, and systemic treatments.
Our mission is to help both patients and physicians through developing effective and innovating drugs.

Information Past News
Jan. 19, 2016
News Release
Our diagnostic business was featured in TV TOKYO's program "Medical office where the chief physician is found in", broadcasted on 18 Jan 2016.
Dec. 14, 2015
News Release
License agreement and business alliance with Liquid Biotech USA, Inc. for cancer detection modality OBP-401 (TelomeScan®)
Dec. 1, 2015
News Release
OBP-401 (TELOMESCAN™) ADOPTED IN CLINICAL TRIALS FOR THE DEVELOPMENT OF NOVEL MOLECULAR TARGETED ANTI-CANCER AGENTS
Nov. 24, 2015
News Release
Announcement of TelomeScan® License Agreement and Business Alliance in North America
Jan. 27, 2015
News Release
On 2/16/2015, Oncolys BioPharma to hold a luncheon seminar by Dr. Shinsaku Togo, MD, Ph.D., Associate Professor, Juntendo University to share recent data from the collaborative research.
Jan. 23, 2015
News Release
Oncolys BioPharma proudly sponsors the 22nd Annual Molecular Medicine Tri-Conference from 2/15-2/20 at Moscone North Convention Center in San Francisco, CA.
Dec. 22, 2014
News Release
IND approval for Phase I clinical trials in the US – New epigenetic targeting cancer drug, OBP-801 –
Nov. 19, 2014
News Release
Initiation of Phase I/II Clinical Study of Telomelysin (OBP-301) - Gene Therapy/Oncolytic Virus for Hepatocellular Carcinoma -
Sep. 25, 2014
Publications
The paper relating to OBP-401 (TelomeScan®) was published on Cancer
Feb. 2014
Publications
The paper relating to OBP-401 (TelomeScan®) was published on Cancer Research
Jan. 22, 2014
News Release
Oncolys BioPharma Initiates Phase I/II Clinical Study of OBP-301(Telomelysin) in Liver Cancer
Dec. 06, 2013
News Release
Oncolys BioPharma was listed on the Tokyo Stock Exchange Mothers
pagetop